Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec - PubMed (original) (raw)
. 2005 Nov 1;41(9):1254-60.
doi: 10.1086/496986. Epub 2005 Sep 20.
Nathalie Saheb, Marie-Andrée Coulombe, Marie-Eve Alary, Marie-Pier Corriveau, Simon Authier, Michel Leblanc, Geneviève Rivard, Mathieu Bettez, Valérie Primeau, Martin Nguyen, Claude-Emilie Jacob, Luc Lanthier
Affiliations
- PMID: 16206099
- DOI: 10.1086/496986
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec
Jacques Pépin et al. Clin Infect Dis. 2005.
Abstract
Background: Since 2002, an epidemic of Clostridium difficile-associated-diarrhea (CDAD) associated with a high case-fatality rate has involved >30 hospitals in the province of Quebec, Canada. In 2003, a total of 55% of patients with CDAD at our hospital had received fluoroquinolones in the preceding 2 months. It has been suggested that massive use of proton pump inhibitors might have facilitated this epidemic.
Methods: To delineate the risk of CDAD associated with specific classes of antibiotics and whether this is modulated by concomitant use of proton pump inhibitors and other drugs altering gastric acidity or gastrointestinal motility, we conducted a retrospective cohort study of patients hospitalized in a teaching hospital in Sherbrooke, Canada, during the period of January 2003 through June 2004. We obtained data on 7421 episodes of care corresponding to 5619 individuals. Patients were observed until they either developed CDAD or died or for 60 days after discharge from the hospital. Adjusted hazard ratios (AHRs) were calculated using Cox regression.
Results: CDAD occurred in 293 patients. Fluoroquinolones were the antibiotics most strongly associated with CDAD (AHR, 3.44; 95% confidence interval [CI], 2.65-4.47). Almost one-fourth of all inpatients received quinolones, for which the population-attributable fraction of CDAD was 35.9%. All 3 generations of cephalosporins, macrolides, clindamycin, and intravenous beta-lactam/beta-lactamase inhibitors were intermediate-risk antibiotics, with similar AHRs (1.56-1.89). Proton pump inhibitors (AHR, 1.00, 95% CI, 0.79-1.28) were not associated with CDAD.
Conclusions: Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.
Comment in
- Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec.
Weiss K. Weiss K. Clin Infect Dis. 2006 Mar 1;42(5):725-7; author reply 727-9. doi: 10.1086/500268. Clin Infect Dis. 2006. PMID: 16447121 No abstract available. - Clostridium difficile-associated diarrhea outbreaks: the name of the game is isolation and cleaning.
Beaulieu M, Thirion DJ, Williamson D, Pichette G. Beaulieu M, et al. Clin Infect Dis. 2006 Mar 1;42(5):725; author reply 727-9. doi: 10.1086/500264. Clin Infect Dis. 2006. PMID: 16447122 No abstract available.
Similar articles
- Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients.
Aseeri M, Schroeder T, Kramer J, Zackula R. Aseeri M, et al. Am J Gastroenterol. 2008 Sep;103(9):2308-13. doi: 10.1111/j.1572-0241.2008.01975.x. Epub 2008 Aug 12. Am J Gastroenterol. 2008. PMID: 18702653 - A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile.
Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S, Thompson A, Jensen B, Wiggs L, Bessette J, Martin J, Clukey J, Gensheimer K, Killgore G, McDonald LC. Kazakova SV, et al. Arch Intern Med. 2006 Dec 11-25;166(22):2518-24. doi: 10.1001/archinte.166.22.2518. Arch Intern Med. 2006. PMID: 17159019 - Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.
Pépin J, Routhier S, Gagnon S, Brazeau I. Pépin J, et al. Clin Infect Dis. 2006 Mar 15;42(6):758-64. doi: 10.1086/501126. Epub 2006 Feb 7. Clin Infect Dis. 2006. PMID: 16477549 - Established and potential risk factors for Clostridum difficile infection.
Vaishnavi C. Vaishnavi C. Indian J Med Microbiol. 2009 Oct-Dec;27(4):289-300. doi: 10.4103/0255-0857.55436. Indian J Med Microbiol. 2009. PMID: 19736396 Review.
Cited by
- Mouthguards: does the indigenous microbiome play a role in maintaining oral health?
Kumar PS, Mason MR. Kumar PS, et al. Front Cell Infect Microbiol. 2015 May 6;5:35. doi: 10.3389/fcimb.2015.00035. eCollection 2015. Front Cell Infect Microbiol. 2015. PMID: 26000251 Free PMC article. - Clostridioides difficile Infections in Inpatient Pediatric Oncology Patients: A Cohort Study Evaluating Risk Factors and Associated Outcomes.
Willis DN, Huang FS, Elward AM, Wu N, Magnusen B, Dubberke ER, Hayashi RJ. Willis DN, et al. J Pediatric Infect Dis Soc. 2021 Apr 3;10(3):302-308. doi: 10.1093/jpids/piaa090. J Pediatric Infect Dis Soc. 2021. PMID: 32766672 Free PMC article. - Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C. Vaishnavi C. Indian J Med Res. 2015 Apr;141(4):398-407. doi: 10.4103/0971-5916.159251. Indian J Med Res. 2015. PMID: 26112840 Free PMC article. Review. - Multicenter Prevalence Study Comparing Molecular and Toxin Assays for Clostridioides difficile Surveillance, Switzerland.
Widmer AF, Frei R, Kuijper EJ, Wilcox MH, Schindler R, Spaniol V, Goldenberger D, Egli A, Tschudin-Sutter S. Widmer AF, et al. Emerg Infect Dis. 2020 Oct;26(10):2370-2377. doi: 10.3201/eid2610.190804. Emerg Infect Dis. 2020. PMID: 32946368 Free PMC article. - Glutamine and alanyl-glutamine increase RhoA expression and reduce Clostridium difficile toxin-a-induced intestinal epithelial cell damage.
Santos AA, Braga-Neto MB, Oliveira MR, Freire RS, Barros EB, Santiago TM, Rebelo LM, Mermelstein C, Warren CA, Guerrant RL, Brito GA. Santos AA, et al. Biomed Res Int. 2013;2013:152052. doi: 10.1155/2013/152052. Epub 2012 Dec 27. Biomed Res Int. 2013. PMID: 23484083 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical